clinical trial · NCT07333742
A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal
LG Chem·phase1·completed·n = 50
Fed ConditionsHealthy VolunteerTest drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mgReference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg
brief summary
Bioequivalence study for the fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg under fed conditions in healthy volunteers
started
Sep 29, 2025
primary completion
Nov 27, 2025
completion
Nov 27, 2025
last updated
Jan 12, 2026
official title
A Randomized, Open Label, Single Oral Dose, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of Gemigliptin/Dapagliflozin/Metformin 50/10/1000 mg and Coadministration of Gemigliptin 50 mg and Dapagliflozin/Metformin 10/1000 mg in Healthy Adults in Fed Condition
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol